儘管已採用傳統內窺鏡療法治療食道及胃靜脈曲張（EV、GV），肝細胞癌（HCC）合併靜脈曲張出血患者的再出血率仍然偏高。據報道，靜脈曲張再出血的次級預防可改善HCC患者的預後，但最佳內窺鏡治療方式尚未明確。在此難以處理的人群中，傳統內窺鏡治療後靜脈曲張再出血率仍然相當高。
適應症：Hepatocellular Carcinoma、Variceal Bleeding
收案條件
納入條件
- Consecutive HCC patients age 18 or older with recent (within 4 weeks of the episode) EV or GV bleeding successfully controlled by conventional endoscopic therapies (VBL for EV or glue injection for GV)
- Able to provide written informed consent to participate in the study and comply with the study procedures
排除條件
- Unable to provide written informed consent
- Contraindications for endoscopy due to underlying comorbidities
- HCC patients with non-variceal source of gastrointestinal bleeding
- Refractory coagulopathy (INR\>1.5) or refractory thrombocytopenia (platelets \<50,000) despite blood product transfusion
- Moribund patients from terminal illness
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。